Follistatin-344 FAQ: common questions answered
Human gene-therapy findings do not establish a dose for follistatin-344 protein vials.
Also called: FS344, FST344, FS-344, Follistatin 344.
Myostatin pathway · Myostatin- and activin-binding protein precursor.
- Is Follistatin-344 FDA-approved? No. Applying FDA’s protein definition to follistatin establishes biological-product status. No FDA-approved product was found.
- How do people take it? Under the skin, daily. Planned ten-day course; first reported injection was subcutaneous.. Source: reported by users, not an established dose.
- What's the difference between Follistatin-344 and Ipamorelin? Follistatin-344: human gene-therapy findings do not establish a dose for follistatin-344 protein vials. Ipamorelin: an experimental peptide that triggers growth hormone release. Why people pair them: a self-use log planned to add it for muscle growth; completed concurrent use was not confirmed.
- Can I take it with Ipamorelin? A self-use log planned to add it for muscle growth; completed concurrent use was not confirmed. No human trial has tested this combination. Added growth-signal and product-quality risks are unknown. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Myostatin-binding proteins are prohibited in and out of competition. Gene or cell doping also falls under M3.
- How do I store it once opened? No validated post-mixing stability, sterility period or beyond-use date was found.
Related to Follistatin-344
- ACE-031: An experimental muscle-growth protein whose Duchenne program stopped over bleeding concerns.
- Ipamorelin: An experimental peptide that triggers growth hormone release.
- IGF-1 LR3: An unapproved growth signal with no human trials found.
- PEG-MGF: A modified MGF peptide with no human dosing studies and uncertain identity in unregulated vials.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- Find product information about medicines, Medicines and Healthcare products Regulatory Agency · MHRA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- Pyrogen and Endotoxins Testing: Questions and Answers, FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Anaphylaxis, NHS · NHS · 2023
- Definition of the Term “Biological Product” Final Regulatory Impact Analysis, FDA · 2020
- Tailor Made Compounding LLC - 594743 - 04/01/2020, FDA · FDA · 2020
- Australian Register of Therapeutic Goods (ARTG), Therapeutic Goods Administration · TGA
- Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application Guidance for Industry, FDA
- Search criteria - Drug Product Database online query, Health Canada · Health Canada
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.